Jefferies Maintains Buy on Structure Therapeutics, Raises Price Target to $79
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Chris Howerton maintains a Buy rating on Structure Therapeutics (NASDAQ:GPCR) and raises the price target from $50 to $79.

September 29, 2023 | 6:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analyst maintains a Buy rating on Structure Therapeutics and raises the price target from $50 to $79.
The news of Jefferies maintaining a Buy rating and raising the price target for Structure Therapeutics is likely to have a positive impact on the company's stock. This is because it signals confidence in the company's future performance, which could attract more investors and potentially drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100